A Double-blind Randomized Trial of Oral Chlorhexidine Gluconate for Treatment of Oral Staphylococcus aureus Colonization in Healthy Children
Year: 2026
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: Background Staphylococcus aureus is the most common cause of skin and soft tissue infection (SSTI). Nasal S. aureus colonization may precede SSTI, and decolonization may decrease SSTI risk. However, many S. aureus–colonized persons are oropharyngeally colonized, sometimes without concomitant nasopharyngeal colonization. However, there are few data on oropharyngeal S. aureus decolonization, especially in children. Methods We performed a prospective, double-blind, randomized controlled clinical trial of twice-daily 0.12% chlorhexidine gluconate (CHG) gargle vs a placebo for 7 days in healthy children oropharyngeally colonized with S. aureus. At each study visit (days 1, 8, 29), throat and nares cultures were performed. All S. aureus isolates underwent spa typing. Results We screened 189 children, 120 (63%) of whom had S. aureus oropharyngeal colonization; of these, 67 (56%) were randomized. The median participant age was 11 years (mean, 11.7), and 27 (40%) were female. In the intention-to-treat population, oropharyngeal colonization at day 8 was 45% (15/33) and 79% (27/34) in the CHG and placebo groups, respectively (P = .004), and 61% (20/33) vs 85% (29/34) at day 29 (P = .03). Among children who were oropharyngeally decolonized at day 8 but positive for S. aureus at day 29, 8/12 (66%) exhibited a new spa type compared with baseline. Conclusions We found that a 7-day 0.12% chlorhexidine gluconate mouthwash regimen significantly reduced S. aureus oropharyngeal colonization compared with placebo. This difference persisted at day 29, suggesting that CHG mouthwash may be a promising adjunctive decolonization agent that may decrease the high SSTI recurrence risk in children.
Source: Open Forum Infectious Diseases
DOI: 10.1093/ofid/ofag072
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,053
Award: G562934659
OpenAlex ID: W7130460701
